Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
April 22, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June...
April 09, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 27, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in...
February 26, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
February 20, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
January 30, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
January 14, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
January 07, 2025 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
November 26, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right